Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-14T22:17:04.902Z Has data issue: false hasContentIssue false
  • English
  • Français

Micro-titration of depot neuroleptic dosages

Published online by Cambridge University Press:  02 January 2018

J. Birch
J. Birch*
Affiliation:
North Shields CMHT, 26a Hawkeys Lane, North Shields, Tyne & Wear
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Depot neuroleptic treatments can be compromised by side-effects unacceptable to users or, more seriously, by tardive dyskinesia (TD). Neuroleptic dosages can be lowered to increase acceptability and decrease the Incidence of TD, but with a greater likelihood of relapse. One argument proposes that many patients changing to lower dosages break down because withdrawal from a neuroleptic is stressful in itself. Research suggests that withdrawal regimes should be radically cautious. A computer tool is offered which can aid clinicians in calculating small reductions.

Type
Original Papers
Information
Psychiatric Bulletin , Volume 20 , Issue 11 , November 1996 , pp. 660 - 661
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1996 The Royal College of Psychiatrists

References

Gilbert, P. L., Harris, M. J., McAdams, L. A., et al (1995) Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Archives of General Psychiatry, 52, 173–188.CrossRefGoogle ScholarPubMed
Green, A. I., Faraone, S. V., Brown, W. A., et al (1992) Neuroleptic Dose Reduction: Clinical and Neuroendocrine Effects. 31st Annual Meeting of the American College of Neuropsychopharmacology. Puerto Rico.Google Scholar
Inderbitzin, L. B., Lewine, R. J., Scheller-Gilkeg, G., et al (1994) A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable, schizophrenic patients. American Journal of Psychiatry, 151, 1753–1759.Google ScholarPubMed
Mosher, L. R. & Burti, L. (1989) Community Mental Health: Principles and Practice. New York: W. W. Norton.Google Scholar
Schooler, N. (1993) Reducing dosage in maintenance treatment of schizophrenia: review and prognosis. British Journal of Psychiatry, 163 (suppl. 22), 158–165.CrossRefGoogle Scholar
Smith, R. C. (1994) Lower-dose therapy with traditional neuroleptics in chronically hospitalized schizophrenic patients. Archives of General Psychiatry, 51, 427–429.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.